2Seventy Bio宣佈將血友病候選藥和Megatal原位基因編輯技術以最高4000萬

快訊 · 06/27 04:11

2Seventy Bio Announces Sale of Hemophilia a Candidate and Megatal in Vivo Gene Editing Technology to Novo Nordisk for up to $40 Million

2Seventy Bio宣佈將血友病候選藥和Megatal原位基因編輯技術以最高4000萬美元的價格出售給諾和諾德。